{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02585622",
      "OrgStudyIdInfo": {
        "OrgStudyId": "NEPHSTROM"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2016-000661-23",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Mario Negri Institute for Pharmacological Research",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "NEPHSTROM for Diabetic Kidney Disease",
      "OfficialTitle": "Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)",
      "Acronym": "NEPHSTROM"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 11, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 22, 2015",
      "StudyFirstSubmitQCDate": "October 22, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 23, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 13, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 14, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Mario Negri Institute for Pharmacological Research",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Leiden University Medical Center",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "ASST Papa Giovanni XXIII, Bergamo, Italy",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Belfast Health and Social Care Trust",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "National University of Ireland, Galway, Ireland",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "NHS Blood and Transplant",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The study will investigate, primarily, the safety, feasibility and tolerability and, secondarily, the preliminary efficacy of an allogeneic bone marrow-derived Mesenchymal Stromal Cell (MSC) therapy (ORBCEL-M) in study subjects with type 2 diabetes (T2D) and progressive diabetic kidney disease (DKD)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Diabetic Kidney Disease"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Diabetic Kidney Disease",
          "Mesenchymal Stromal Cells (MSC)",
          "immune response",
          "allogeneic",
          "disease progression"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Other",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "48",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Bone marrow-derived Mesenchymal Stromal Cells",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Stromal Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Cryostor CS10",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Stromal Cells",
            "InterventionDescription": "Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Bone marrow-derived Mesenchymal Stromal Cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Allogeneic Cellular Therapy (NEPHSTROM ORBCEL-M)"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "Volume total of fluid infused: 40 ml",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cryostor CS10"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Cryostor CS10"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.",
            "PrimaryOutcomeDescription": "At each visit overall clinical condition of the patient will be evaluated and any adverse event wil be recorded.",
            "PrimaryOutcomeTimeFrame": "Changes from baseline to study completion, up to 18 months after cell or placebo infusion."
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Glomerular filtration rate (GFR)",
            "SecondaryOutcomeDescription": "GFR will be measured by plasma clearance of unlabelled exogenous marker Iohexol and estimated by CKD-EPI and MDRD equations.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline up to 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Urinary Albumin/Creatinine Ratio (ACR)",
            "SecondaryOutcomeDescription": "ACR will be measured on spot morning urine samples.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline at 6 months and then every six months to study completion,up to 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Urinary albumin excretion (UAE).",
            "SecondaryOutcomeDescription": "UAE will be measured on 24h urine samples using standardized methods.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline at 6 months and then every six months to study completion,up to 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Fasting blood glucose (target <126mg/dL)",
            "SecondaryOutcomeTimeFrame": "Proportion of study participants within target range (<126mg/dL) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion)."
          },
          {
            "SecondaryOutcomeMeasure": "HbA1c (target <75mmol/mol or <9%)",
            "SecondaryOutcomeTimeFrame": "Proportion of study participants within target range (<75mmol/mol or <9%) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion)."
          },
          {
            "SecondaryOutcomeMeasure": "Total cholesterol (target <200 mg/dl)",
            "SecondaryOutcomeTimeFrame": "Proportion of study participants within target range (<200 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion)."
          },
          {
            "SecondaryOutcomeMeasure": "LDL cholesterol (target <100 mg/dl)",
            "SecondaryOutcomeTimeFrame": "Proportion of study participants within target range (<100 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion)."
          },
          {
            "SecondaryOutcomeMeasure": "Triglycerides (target <170 mg/dl)",
            "SecondaryOutcomeTimeFrame": "Proportion of study participants within target range (<170 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion)."
          },
          {
            "SecondaryOutcomeMeasure": "Arterial blood pressure (the target value <130/80 mmHg)",
            "SecondaryOutcomeTimeFrame": "Proportion of study participants within target range (<130/80 mmHg)at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion)."
          },
          {
            "SecondaryOutcomeMeasure": "Quality of life",
            "SecondaryOutcomeDescription": "Quality of life will be evaluated by the administration of SF36 questionnaire.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Quality of life",
            "SecondaryOutcomeDescription": "Quality of life will be evaluated by the administration of EQ-5D-5L questionnaire.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Anti-HLA antibody development",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 3,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Inflammation and fibrosis related soluble mediators",
            "SecondaryOutcomeDescription": "Blood and urine bio-chip-based multiplex assay",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.",
            "SecondaryOutcomeDescription": "Biomarkers will include sTNFR1, sTNFR2, Il-6,TNF-alfa, IL-1beta, MCP-1 (CCL2), IL-8, FGF21.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.",
            "SecondaryOutcomeDescription": "Biomarkers will include Cystatin C, NGAL, Adiponectin, Leptin.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.",
            "SecondaryOutcomeDescription": "Biomarkers will include sTNFR1, sTNFR2, Il-6,TNF-alfa, IL-1beta, MCP-1 (CCL2), IL-8.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion."
          },
          {
            "SecondaryOutcomeMeasure": "Cost-effectiveness of cell therapy",
            "SecondaryOutcomeDescription": "Cost-effectiveness of cell therapy will be evaluated by providing the patients with a healthcare resource diary.",
            "SecondaryOutcomeTimeFrame": "Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion."
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale and female ≥ 40 years and <85 years old. ;\nT2D for 3 or more years under a clinician with mandated responsibility for management of the patients to national guidelines;\nUrinary albumin excretion (UAE) ≥ 60 µg/min (in a 24 hour urine collection) and urine albumin-to-creatinine ratio (UACR) ≥ 88 mg/g (≥ 10 mg/mmol) (in a spot morning urine collection);\nEstimated GFR (eGFR) 30-50 ml/min/1.73 m^2 by the CKD-EPI equation on 2 or more consecutive measurements at least 30 days apart within the past 6 months;\nA documented decline of eGFR of ≥ -10ml/min/1.73 m^2 over the past 3 years or documented rate of eGFR decline of ≥ -5 ml/min/1.73 m^2 year based on 3 or more consecutive readings at least 90 days apart in the past 18 months;\nLack of suspicion of renal diagnosis other than DKD;\nWilling and able to provide written informed consent.\n\nExclusion Criteria:\n\nCurrent resting systolic BP ≥ 150 mmHg and current resting diastolic BP ≥ 90 mmHg in a clinical setting, despite treatment with 3 hypertensive agents of different classes (including one diuretic), measured in a quiet environment with morning medications already taken;\nInitiation of a new anti-hypertensive agent within the past 6 months\n\nIncrease the dose of an anti-hypertensive agent by ≥ 100% of the previous dose within the past 3 months\n\nExclusion criteria related to glycaemic control:\n\nCurrent HbA1c > 75 mmol/mol (> 9%)\nInitiation of a new hypoglycaemic agent within the past 6 months\n\nIncrease the dose of a hypoglycaemic agent by ≥ 100% of the previous dose within the past 3 months\n\nExclusion criteria related to dyslipidaemia:\n\nCurrent fasting total cholesterol > 7 mmol/l\nCurrent fasting total triglycerides > 3.5 mmol/l\n\nInitiation of a new lipid lowering agent within the past 6 months\n\nOther exclusion criteria:\n\nChronic lung or liver disease;\nCardiovascular events (myocardial infarction, stroke or acute limb ischemia) within 6 months prior to enrolment;\nCurrent or history within 6 months prior to enrolment of NYHA class III or IV heart failure;\nOther concomitant disease or conditions in the opinion of the investigator that are likely to pose risk to the patient and that would render the patient unsuitable for participation or that could impair patient safety or ability to participate in the study, such as active malignancy;\nIrreversible disease or condition for which 6-month mortality is estimated to be greater than 50%;\nPositive screening test for clinically significant anti-HLA antibodies. An initial antibody screening with Luminex® multi-antigen beads to detect class I and class II MHC antibodies followed by a Luminex single antigen bead assay to determine the specificity of any antibody detected. Potential study subjects with positive screening for any clinically significant anti-HLA antibody will be excluded and will not be eligible to participate in the NEPHSTROM clinical study (MFI>1500);\nHistory or presence of any medical condition or disease which, in the opinion of the Investigator may place the participant at unacceptable risk for study participation;\nChildbearing potential without use of effective acceptable methods of contraception. Women of childbearing potential can only be included in the study if a pregnancy test is negative at the screening visit (V1) and at baseline visit (V2) if they agree to use adequate contraception. Adequate contraception is defined as any combination of at least two effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate) or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or have had surgical treatment such as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.\nPregnancy or lactating;\nParticipation in other investigational medicinal product (IMP) trials within 30 days before the inclusion or concurrent to this study (18 month follow-up);\nInability to understand the potential risks and benefits of the study;\nLegal incapacity.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "40 Years",
      "MaximumAge": "85 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Giuseppe Remuzzi, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "003903542131",
            "CentralContactEMail": "giuseppe.remuzzi@marionegri.it"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Giuseppe Remuzzi, MD",
            "OverallOfficialAffiliation": "ASST Papa Giovanni XXIII, Bergamo, Italy/IRCCS - Mario Negri Institute for Pharmacological Research",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Mattew Griffin, MD",
            "OverallOfficialAffiliation": "National University of ireland - Galway University Hospital -Regenerative Medicine Institute",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Paul Cockwell, MD",
            "OverallOfficialAffiliation": "University Hospital Birmingham NHS Foundation Trust",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Peter Maxwell, MD",
            "OverallOfficialAffiliation": "Belfast Health and Social Care Trust - Belfast City Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "National University of ireland - Galway University Hospital -Regenerative Medicine Institute",
            "LocationStatus": "Recruiting",
            "LocationCity": "Galway",
            "LocationCountry": "Ireland",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Matthew Griffin, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "00353 91 495107",
                  "LocationContactEMail": "matthew.griffin@nuigalway.ie"
                }
              ]
            }
          },
          {
            "LocationFacility": "ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò",
            "LocationStatus": "Recruiting",
            "LocationCity": "Bergamo",
            "LocationState": "BG",
            "LocationZip": "24027",
            "LocationCountry": "Italy",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Piero Ruggenenti, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "0039 035 45351",
                  "LocationContactEMail": "piero.ruggenenti@marionegri.it"
                }
              ]
            }
          },
          {
            "LocationFacility": "Belfast Health and Social Care Trust - Belfast City Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Belfast",
            "LocationCountry": "United Kingdom",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Peter Maxwell, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "0044 28 95049751",
                  "LocationContactEMail": "peter.maxwell@belfasttrust.hscni.net.as"
                }
              ]
            }
          },
          {
            "LocationFacility": "University Hospital Birmingham NHS Foundation Trust - Queen Elizabeth Medical Centre",
            "LocationStatus": "Recruiting",
            "LocationCity": "Birmingham",
            "LocationCountry": "United Kingdom",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Paul Cockwell, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "0044 121 3714181",
                  "LocationContactEMail": "paul.cockwell@uhb.nhs.uk"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007674",
            "ConditionMeshTerm": "Kidney Diseases"
          },
          {
            "ConditionMeshId": "D000003928",
            "ConditionMeshTerm": "Diabetic Nephropathies"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          },
          {
            "ConditionAncestorId": "D000048909",
            "ConditionAncestorTerm": "Diabetes Complications"
          },
          {
            "ConditionAncestorId": "D000003920",
            "ConditionAncestorTerm": "Diabetes Mellitus"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafAsFound": "Kidney Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6275",
            "ConditionBrowseLeafName": "Diabetic Nephropathies",
            "ConditionBrowseLeafAsFound": "Diabetic Kidney Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19712",
            "ConditionBrowseLeafName": "Disease Progression",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M25157",
            "ConditionBrowseLeafName": "Diabetes Complications",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          }
        ]
      }
    }
  }
}